Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 23;83(16):1557-1567.
doi: 10.1016/j.jacc.2024.01.039.

Measurement and Application of Incidentally Detected Coronary Calcium: JACC Review Topic of the Week

Shyon Parsa  1 , Adam Saleh  2 , Viraj Raygor  3 , Natalie Hoeting  4 , Anjali Rao  4 , Ann Marie Navar  4 , Anand Rohatgi  4 , Fernando Kay  5 , Suhny Abbara  5 , Amit Khera  4 , Parag H Joshi  6
Affiliations
Free article
Review

Measurement and Application of Incidentally Detected Coronary Calcium: JACC Review Topic of the Week

Shyon Parsa et al. J Am Coll Cardiol. .
Free article

Abstract

Coronary artery calcium (CAC) scoring is a powerful tool for atherosclerotic cardiovascular disease risk stratification. The nongated, noncontrast chest computed tomography scan (NCCT) has emerged as a source of CAC characterization with tremendous potential due to the high volume of NCCT scans. Application of incidental CAC characterization from NCCT has raised questions around score accuracy, standardization of methodology including the possibility of deep learning to automate the process, and the risk stratification potential of an NCCT-derived score. In this review, the authors aim to summarize the role of NCCT-derived CAC in preventive cardiovascular health today as well as explore future avenues for eventual clinical applicability in specific patient populations and broader health systems.

Keywords: cardiovascular imaging; coronary artery calcium; heart disease; patient-centered care pathways; personalized medicine; preventive health.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Joshi has received grant support from Novartis, Novo Nordisk, Kaneka, and Amgen; has received consulting fees from Novartis; and has received equity in G3 Therapeutics. Dr Rao has received grant support from Quest; and has received consulting fees from CSL, Raydel, Johnson and Johnson, JP Morgan, and Quest. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Similar articles

See all similar articles

Cited by

LinkOut - more resources